Jeffrey D. Mowery Named Site Head/General Manager
Naofumi Kagami Named Site Head/General Manager
Kasper Møller named Chief Technical Officer
BOTHELL, WA. -- May 15, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing
On Thursday, April 25th, AGC Biologics welcomed U.S. Congresswoman, representing Washington’s 1st District, Suzan DelBene to our global headquarters in Seattle, WA. The purpose of Congresswoman DelBene’s visit was to highlight our high school internship program, Project BioPath, a first of its kind offering designed to give high school students hands-on training, real-world work experience and a pathway to job opportunities at AGC Biologics and other biotechnology companies. We are proud and excited about the success and visibility this project is gaining and Congresswoman DelBene’s visit was an inspiration for us to continue investing in the talent of tomorrow.
BOTHELL, Washington, April 2, 2019 /PRNewswire/ --
AGC Biologics today announces a change in executive leadership. Dr. Gustavo Mahler has decided to leave his position as CEO effective April 30th, 2019 after a 10 year tenure with CMC Biologics and AGC Biologics. Dr. Mahler will continue on as a member of the Board of Directors . Patricio Massera, previously the Chief Operating Officer for AGC Biologics, will succeed Dr. Mahler as the Chief Executive Officer, effective May 1st 2019.
Gustavo joined AGC Biologics (previously CMC Biologics) in 2008 as President. In 2010, he was named global Chief Operations Officer and in January, 2016 he became Chief Executive Officer. "The transition of Patricio to the CEO role is carefully planned," stated Gustavo. "It has been a sincere pleasure to lead AGC Biologics and I am proud of all we accomplished. I am thankful for the opportunity to have worked with a world-class team of professionals and advance the pipeline of our customers to market."
On Friday, March 22nd, AGC Biologics welcomed Washington State Governor Jay Inslee to its global headquarters in Bothell, WA. Along with the Governor, we also welcomed representatives from Edmonds School District, our educational partner. The purpose of the Governor’s visit was to highlight our new paid high school internship program, Project BioPath, to train students from our region to fill jobs we have to offer. The new internship program is designed to give high school students hands-on training, real-world work experience and a pathway to job opportunities at AGC Biologics and other biotechnology companies. With the launch of Project BioPath, we are pursuing a strategy to increase the available talent pool for our company and the greater industry.
COPENHAGEN, Denmark and AMSTERDAM, Feb. 19, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and Calypso Biotech B.V. (Calypso), a biotechnology company focused on the development of novel therapeutic antibodies in the inflammation/autoimmune therapeutic areas announced today that they have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15). Under the agreement, AGC Biologics will develop and scale up a process for cGMP manufacture of CALY-002 in its world class facility in Copenhagen, Denmark to support Calypso's clinical trials in Europe.
IL-15 is an immune checkpoint cytokine that controls inflammation as well as the fate of multiple immune cells. Especially, IL-15 was recently recognized as a key factor in the survival of tissue-resident memory T cells, a population of immune cells involved in disease maintenance and recurrence. Calypso scientists believe that targeting tissue-resident memory T cells with CALY-002 offers significant advantages and potential in multiple autoimmune indications, including unprecedented disease-modifying effects.
"We are pleased to be working with Calypso on this exciting and innovative monoclonal antibody product," said Gustavo Mahler, PhD, Chief Executive Officer of AGC Biologics "With our extensive experience developing and manufacturing monoclonal antibody products, we are well positioned to help Calypso deliver this innovative antibody treatment to patients."
"We selected CMC Biologics as our manufacturing partner because of their ability to support our accelerated program for CALY-002, since they have extensive experience working with monoclonal antibodies combined with their very broad development and manufacturing capabilities," said Alain Vicari, DVM, PhD, Chief Executive Officer of Calypso. "The successful process development and manufacture of CALY-002 is critical to Calypso meeting our aggressive clinical development timelines."
About Calypso Biotech
Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Calypso Biotech is headquartered in Amsterdam, the Netherlands, with offices and laboratories in Geneva, Switzerland, and is also a resident company of Johnson & Johnson Innovation -JLABS (JLABS @ BE) in Beerse, Belgium, a premier life science incubator program. For more information on Calypso Biotech, please see https://www.calypsobiotech.com
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization, with a strong commitment to deliver the highest standard of service to our clients. AGC Biologics has an extensive network of cGMP facilities in the US, Europe and Asia. We offer deep industry expertise, innovative solutions and technologies, and customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial, for mammalian and microbial. We forge exceptionally strong partnerships with our clients, and we never lose sight of our pledge to deliver reliable and compliant drug substance supply, on time. For more information, visit www.agcbio.com.
Calypso Biotech Media Contact Information:
Alain VICARI DVM, PhD
Chief Executive Officer
Calypso Biotech BV
AGC Biologics Media Contact Information:
Head of Global Marketing
AGC Biologics CEO Gustavo Mahler recently sat down with Global Business Reports to discuss our business and his vision for our future.
AGC Biologics was created following AGC Asahi Glass’ acquisition of Biomeva and CMC Biologics. Could you provide an overview of how the three organizations have been integrated?
Following the acquisitions of CMC Biologics and Biomeva, we began to identify how to integrate all entities under the single AGC Biologics brand. There are a number of challenges that come with rebranding because all stakeholders need to be accounted for. Thus, we carried out a thorough integration period across nine different streams, including operations, quality, I.T. and supply chain. We also developed a strategic plan to grow the business. We had an ambitious capital investment approach, which included expansion at our Denmark
New facility will include comprehensive mammalian process development and manufacturing capabilities
BOTHELL, WA and CHIBA, JAPAN; Sept 20, 2018 ─ AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other
types of therapeutic proteins.